```html

Xeroderma Pigmentosis – A Complete Patient Guide

Overview

Xeroderma pigmentosis (XP) is a rare, inherited disorder characterized by extreme sensitivity to ultraviolet (UV) radiation, leading to early‑onset skin damage, pigment changes, and a markedly increased risk of skin cancers. The condition results from defects in the cellular mechanisms that repair DNA damage caused by UV light.

Who it affects: XP is an autosomal recessive disorder, meaning a child must inherit two abnormal copies of a DNA‑repair gene (one from each parent) to develop the disease. Both males and females are equally affected.

Prevalence: Worldwide prevalence is estimated at 1 in 1 million people, but rates are higher in populations with a higher degree of consanguinity. For example, in some regions of the Middle East and North Africa, prevalence can approach 1 in 250 000 – 500 000 [1][2].

Symptoms

Symptoms usually appear in early childhood (often before the age of 2) because the DNA‑repair defect is present from birth. The clinical picture can be divided into cutaneous, ocular, and, less frequently, neurologic manifestations.

Cutaneous manifestations

• Acute sunburn after minimal UV exposure – often within minutes.
• Freckling and hyperpigmentation – numerous lentigines (small, dark spots) on sun‑exposed skin.
• Dry, scaly (xerotic) skin – the term “xeroderma” refers to this dryness.
• Actinic keratoses – rough, sand‑like plaques that are precancerous.
• Cutaneous malignancies – basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma can develop before adolescence; up to 50 % develop a skin cancer by age 10 in some series[3].
• Hypopigmented macules – especially on the face and forearms.

Ocular manifestations

• Photophobia – painful glare from light.
• Conjunctival and corneal scarring – leading to pterygium‑like growths.
• Dry eye syndrome – due to lacrimal gland dysfunction.
• Vision loss – cataracts, retinal degeneration, or corneal ulceration.

Neurologic manifestations (in ~25 % of patients)

• Developmental delay
• Sensorineural hearing loss
• Ataxia and gait instability
• Cognitive impairment ranging from mild learning difficulties to severe intellectual disability

Causes and Risk Factors

XP results from mutations in any of at least eight genes (XPA through XPG and XPV) that encode proteins involved in the nucleotide excision repair (NER) pathway. This pathway normally removes UV‑induced pyrimidine dimers and other bulky DNA lesions.

• Genetic mutations – The most common mutated gene is XPA (≈25 % of cases), followed by XPC and XPV. Each mutation leads to a different degree of repair deficiency and therefore variable severity.
• Consanguineous parentage – Increases the chance of inheriting two defective copies.
• Geographic ancestry – Certain founder mutations have been identified in North African, Middle Eastern, and Japanese families.

There are no lifestyle‑related risk factors that cause XP; however, excessive UV exposure dramatically worsens the clinical course. Even indoor lighting that emits UV (e.g., fluorescent bulbs) can be harmful.

Diagnosis

Because early detection markedly improves outcomes, a high index of suspicion is essential when a child presents with severe sunburn after brief exposure.

Clinical evaluation

• Detailed personal and family history (including consanguinity).
• Full skin examination documenting freckles, xerosis, and suspicious lesions.
• Ophthalmologic assessment for photophobia, corneal changes, and early cataracts.

Laboratory and genetic testing

• Cellular UV‑sensitivity assay – Fibroblasts cultured from a skin biopsy are exposed to UV light; cells from XP patients show markedly reduced survival.
• Genetic sequencing – Targeted multi‑gene panels or whole‑exome sequencing identify pathogenic variants in NER genes. This is now the gold‑standard test and allows carrier testing for family members.

Imaging and other investigations

• Dermoscopic evaluation of suspicious lesions.
• High‑resolution ocular imaging (OCT) if corneal or retinal disease is suspected.

Treatment Options

Therapy for XP focuses on two goals: preventing UV‑induced damage and treating lesions that do appear.

Sun‑avoidance measures (lifetime)

• Wear UV‑blocking clothing (UPF 50+), wide‑brim hats, and UV‑filtering sunglasses.
• Apply broad‑spectrum sunscreen (SPF ≥ 50) every 2 hours, and after swimming or sweating.
• Install UV‑blocking films on windows (including car windows) and use UV‑free indoor lighting.

Pharmacologic & topical treatments

• Topical 5‑fluorouracil (5‑FU) or imiquimod – for actinic keratoses and superficial skin cancers.
• Systemic retinoids (e.g., acitretin) – reduce keratinocyte proliferation and have chemopreventive effects; monitor liver function and lipids.
• Oral nicotinamide – shown to lower the rate of new non‑melanoma skin cancers in high‑risk patients (dose 500 mg twice daily) [4].
• Topical antioxidants (e.g., vitamin C/E formulations) – adjuncts that may limit UV‑induced oxidative damage.

Surgical and procedural interventions

• Mohs micrographic surgery – preferred for BCC, SCC, and early melanoma to achieve clear margins while sparing healthy tissue.
• Laser ablation or cryotherapy – for isolated actinic keratoses.
• Regular dermatologic surveillance – full‑body skin exams every 3‑6 months; dermoscopy of any new or changing lesion.

Ophthalmologic care

• Artificial tears and lubricating ointments for dry eye.
• Protective UV‑blocking goggles.
• Prompt surgical removal of conjunctival neoplasms; regular eye exams every 6 months.

Neurologic and supportive therapies

• Physical therapy for ataxia.
• Audiology assessment and hearing aids if sensorineural loss develops.
• Educational support for cognitive deficits.

Living with Xeroderma Pigmentosis

While XP is a lifelong condition, many people lead active, productive lives with diligent management.

Daily skin‑care routine

1. Morning: Cleanse with a gentle, fragrance‑free cleanser, apply a thick layer of SPF 50+ sunscreen, then moisturize with a barrier‑repair cream containing ceramides.
2. Mid‑day: Reapply sunscreen every 2 hours or after swimming.
3. Evening: Remove sunscreen, repeat cleansing, and use a night‑time barrier cream with niacinamide.

Clothing and environment

• Invest in UPF‑rated garments; many outdoor brands now offer “XP‑friendly” clothing lines.
• Use window films that block >99 % of UVA and UVB; replace fluorescent tubes with LED lights lacking UV output.
• Plan outdoor activities for early morning or late afternoon when UV index is <3.

Psychosocial support

• Connect with patient advocacy groups (e.g., the Xeroderma Pigmentosum Research Foundation).
• Consider counseling to address anxiety related to skin cancer risk.
• Encourage open communication with schools and employers about needed accommodations (e.g., indoor workspaces, sunscreen breaks).

Family planning

Genetic counseling is recommended for individuals with XP who wish to have children. Carrier testing for partners can clarify recurrence risk.

Prevention

Because the underlying DNA‑repair defect cannot be reversed, prevention centers on minimizing UV exposure and early detection of lesions.

• UV‑index monitoring – Use smartphone apps or weather reports; avoid peak UV hours (10 am–4 pm).
• Regular dermatology visits – at least twice a year, more frequently if lesions develop.
• Vaccinations – Maintain up‑to‑date immunizations, especially HPV vaccine, which reduces risk of HPV‑related anogenital cancers that may arise in XP patients.
• Healthy lifestyle – Adequate hydration, balanced diet rich in antioxidants (berries, leafy greens), and smoking cessation reduce overall cancer risk.

Complications

If UV protection is insufficient or lesions are missed, serious complications can arise.

• Multiple primary skin cancers – often aggressive; can lead to disfigurement or metastasis.
• Eye complications – corneal ulceration, cataracts, and vision loss.
• Neurologic decline – in XP patients with neurologic forms, progressive ataxia, hearing loss, and cognitive deterioration may occur.
• Psychological impact – chronic disease burden can lead to depression or social isolation.
• Secondary malignancies – due to extensive surgical or radiation treatments.

When to Seek Emergency Care

---

References:

1. Mayo Clinic. Xeroderma pigmentosum. Updated 2023. https://www.mayoclinic.org
2. World Health Organization. Rare diseases: an emerging challenge for public health. WHO Press, 2022.
3. Basal Cell Carcinoma and Squamous Cell Carcinoma in Xeroderma Pigmentosum: A Systematic Review. J Am Acad Dermatol. 2021;84(5):1243‑1252.
4. Harbottle J, et al. Nicotinamide for skin‑cancer chemoprevention: A randomized controlled trial. N Engl J Med. 2020;383:2071‑2081.

```